Shares of Diurnal Group plc (LON:DNL – Get Rating) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 53.28 ($0.69) and traded as low as GBX 33.01 ($0.43). Diurnal Group shares last traded at GBX 34.70 ($0.45), with a volume of 56,922 […]
12 January 2021 | 09:22am
StockMarketWire.com - Pharmaceutical company Diurnal sad it had filed a market authorisation application to the UK Medicines and Healthcare products Regulatory Agency for its drug to treat adult and adolescent patients with the rare condition congenital adrenal hyperplasia.
The application in the UK followed an application in the EU to the European Medicines Agency in December 2019, with approval for both applications anticipated in the first quarter of 2021, the company said. The submission for the MHRA was based on the same application submitted to the EMA in December 2019, including detailed analysis of data from the company s Phase 3 study, an open-label safety extension study of Chronocort and written formal scientific advice received in April 2019 confirming the clinical and regulatory pathway for Chronocort as a treatment for patients with CAH, the company said.